Addex gets $1M MJFF grant to test potential dyskinesia drug

03/20/2013 | Pharmaceutical Business Review Online

The Michael J. Fox Foundation awarded Addex Therapeutics a $1 million grant to support clinical trials of dipraglurant against levodopa-induced dyskinesia among Parkinson's disease patients. Dipraglurant, an oral, small molecule allosteric modulator, selectively inhibits metabotropic glutamate receptor 5.

View Full Article in:

Pharmaceutical Business Review Online

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr Statistician I (US/TB/00/0028/SL)
Santa Clara, CA
Food & Drug Associate
Washington, D.C., DC
Senior Manager, Gaps in Care
UAW Retiree Medical Benefits Trust
Detroit, MI
Compliance Director
Abbott Laboratories
Santa Clara, CA
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA